Der blev observeret en reduktion i risikoen for objektiv sygdomsprogression hos de fleste patientgrupper, men den var tydeligst hos de grupper med størst risiko for sygdomsprogression.
A reduction in risk of objective disease progression was seen across most patient groups but was most evident in those at highest risk of disease progression.